Add to Favourites
To login click here
Drug developers are beginning to use Artificial Intelligence (AI) technology to systematically exploit the physical mechanisms behind macromolecule formation in nature in order to design therapeutic proteins. Evozyne, a company that combines the principles of evolution and deep learning technology, is a leader in this field. AI technology is expected to help improve the speed and accuracy of therapeutic protein design.
